Byondis
Willem Klaassen is an accomplished professional in clinical development with extensive experience in leadership roles across multiple pharmaceutical companies. Currently, Willem serves as the Director of Clinical Development at Byondis since May 2023. Prior to this position, Willem was the Director of Clinical Projects at Xenikos B.V., where responsibilities included the clinical development of T-Guard for steroid-refractory acute Graft-versus-Host Disease. At Acerta Pharma B.V., Willem held the title of Head of Clinical Operations and played a key role in establishing a robust Clinical Operations group and leading a significant global study, ACE-LY-004, for Acalabrutinib. Additional previous roles include Associate Director of Clinical Operations at Merck and various project management positions at Schering-Plough Research Institute and Organon. Willem holds an MSc in Medical Biology from Radboud University and has obtained a Project Management Professional certification from the Project Management Institute, alongside extensive training in management and personal effectiveness.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.